MedTrace Logo

Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

NCT01835496 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-07-24

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the pharmacokinetics of deferiprone and its 3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in patients with sickle cell disease.

Conditions

Interventions

DRUG

single 1500 mg dose of Ferriprox

A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions

Sponsors & Collaborators

  • ApoPharma

    lead INDUSTRY

Principal Investigators

  • Denis Soulieres, MD · CHUM - Hôpital Notre-Dame

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01835496 on ClinicalTrials.gov